George Jay Goldsmith Sells 23,881 Shares of COMPASS Pathways plc (NASDAQ:CMPS) Stock

COMPASS Pathways plc (NASDAQ:CMPS) major shareholder George Jay Goldsmith sold 23,881 shares of the stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total transaction of $203,704.93. Following the completion of the sale, the insider now directly owns 3,986,523 shares of the company’s stock, valued at approximately $34,005,041.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

George Jay Goldsmith also recently made the following trade(s):

• On Monday, April 1st, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.96, for a total transaction of $230,720.00.
• On Tuesday, March 12th, George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock. The stock was sold at an average price of $10.58, for a total transaction of $166,529.20.
• On Monday, January 22nd, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.35, for a total transaction of $215,012.50.
• On Friday, January 19th, George Jay Goldsmith sold 20,205 shares of COMPASS Pathways stock. The shares were sold at an average price of $7.99, for a total transaction of $161,437.95.

COMPASS Pathways Price Performance

Shares of CMPS stock opened at $8.38 on Friday. The firm has a market cap of $519.06 million, a P/E ratio of -3.51 and a beta of 2.48. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.33 and a quick ratio of 13.33. COMPASS Pathways plc has a 1-year low of $5.01 and a 1-year high of $12.75. The firm has a fifty day moving average of $9.94 and a two-hundred day moving average of $8.35.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.16). As a group, research analysts anticipate that COMPASS Pathways plc will post -2.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC grew its holdings in COMPASS Pathways by 7.6% during the 4th quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock worth $22,915,000 after acquiring an additional 186,040 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of COMPASS Pathways in the 3rd quarter valued at about $597,000. Armistice Capital LLC acquired a new position in shares of COMPASS Pathways in the 3rd quarter valued at about $2,960,000. Vivo Capital LLC acquired a new position in shares of COMPASS Pathways in the 3rd quarter valued at about $11,899,000. Finally, AE Wealth Management LLC acquired a new position in shares of COMPASS Pathways in the 3rd quarter valued at about $106,000. 46.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CMPS has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a report on Friday, March 1st. Finally, Morgan Stanley initiated coverage on shares of COMPASS Pathways in a report on Monday, April 1st. They set an “overweight” rating and a $30.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $47.40.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.